In February 2021 MediSieve has been promoted to being a Gold Company within the EIT Health Investor Network, achieving the highest possible rank. 

The EIT Health Investor Network is an early stage equity funding for healthcare start-ups. The Networks connects qualified companies seeking early-stage funding with the first pan-European consortium of more than 80 investors across 18 countries. The Network helps start-ups navigate the lengthy and complex processes of raising funds, especially when launching across multiple markets in Europe. The participating investors are passionate about accelerating start-ups in order to bring innovative ideas to health markets as quickly as possible. 

The Gold Label distinguishes MediSieve from the rest of participants as being a very strong project with a vast potential. The recognition will provide MediSieve with more novel mentoring and investment opportunities, allowing quicker development.

MediSieve thanks the team at EIT for all the help and support!

More about EIT:

https://eithealth.eu/programmes/investor-network/

About MediSieve

MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk

Sort by: Newest First Oldest First Most Popular Most unliked